These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. LH-RH analogues: I. Their impact on reproductive medicine. Schally AV Gynecol Endocrinol; 1999 Dec; 13(6):401-9. PubMed ID: 10685334 [TBL] [Abstract][Full Text] [Related]
3. Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone. Engel JB; Schally AV Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):157-67. PubMed ID: 17237842 [TBL] [Abstract][Full Text] [Related]
4. Potential use of analogs of luteinizing hormone-releasing hormones in the treatment of hormone-sensitive neoplasms. Schally AV; Redding TW; Comaru-Schally AM Cancer Treat Rep; 1984 Jan; 68(1):281-9. PubMed ID: 6362868 [TBL] [Abstract][Full Text] [Related]
5. [History of clinical studies on hypothalamic hormone analogs in Mexico]. Schally AV; González Bárcena D Gac Med Mex; 2006; 142(4):315-25. PubMed ID: 17022307 [TBL] [Abstract][Full Text] [Related]
6. Hypothalamic hormones and cancer. Schally AV; Comaru-Schally AM; Nagy A; Kovacs M; Szepeshazi K; Plonowski A; Varga JL; Halmos G Front Neuroendocrinol; 2001 Oct; 22(4):248-91. PubMed ID: 11587553 [TBL] [Abstract][Full Text] [Related]
7. Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis. Schally AV Peptides; 1999; 20(10):1247-62. PubMed ID: 10573298 [TBL] [Abstract][Full Text] [Related]
8. New approaches to the therapy of various tumors based on peptide analogues. Schally AV Horm Metab Res; 2008 May; 40(5):315-22. PubMed ID: 18491250 [TBL] [Abstract][Full Text] [Related]
9. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers. Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524 [TBL] [Abstract][Full Text] [Related]
11. Detection and partial characterization of receptors for [D-Trp6]-luteinizing hormone-releasing hormone and epidermal growth factor in human endometrial carcinoma. Srkalovic G; Wittliff JL; Schally AV Cancer Res; 1990 Mar; 50(6):1841-6. PubMed ID: 2155060 [TBL] [Abstract][Full Text] [Related]
15. Complete regression of MX-1 human breast carcinoma xenografts after targeted chemotherapy with a cytotoxic analog of luteinizing hormone-releasing hormone, AN-207. Kahán Z; Nagy A; Schally AV; Halmos G; Arencibia JM; Groot K Cancer; 1999 Jun; 85(12):2608-15. PubMed ID: 10375109 [TBL] [Abstract][Full Text] [Related]
16. G protein-coupled receptors of the hypothalamic-pituitary-gonadal axis: a case for Gnrh, LH, FSH, and GPR54 receptor ligands. Heitman LH; Ijzerman AP Med Res Rev; 2008 Nov; 28(6):975-1011. PubMed ID: 18561294 [TBL] [Abstract][Full Text] [Related]
17. Analysis of clinical studies with natural and synthetic luteinizing hormone-releasing hormone in man. Kastin AJ; Schally AV; Zarate A; Arimura A; Gonzalez-Barcena D; Medeiros-Neto CA; Schalch DS Isr J Med Sci; 1974 Oct; 10(10):1305-13. PubMed ID: 4611964 [TBL] [Abstract][Full Text] [Related]
18. Correlation of annual change of luteinizing hormone-releasing hormone (LH-RH) with gonadal development in amphioxus. Fang YQ; Wang H; Zhang CL Sci China B; 1991 Jul; 34(7):814-22. PubMed ID: 1878143 [TBL] [Abstract][Full Text] [Related]
19. Evaluating the role of exogenous luteinizing hormone in poor responders undergoing in vitro fertilization with gonadotropin-releasing hormone antagonists. Chung K; Krey L; Katz J; Noyes N Fertil Steril; 2005 Aug; 84(2):313-8. PubMed ID: 16084870 [TBL] [Abstract][Full Text] [Related]